Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 224

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 224
---
 into an amendment to such agreement to extend the termination date of the agreement to December 31, 2024.

On August 26, 2024, the Company filed a proxy statement with the SEC containing a proposal to stockholders to amend the Iris Certificate of Incorporation to extend the date by which the Company must consummate a business combination from September 9, 2024 to December 31, 2024. The Company’s stockholders approved the amendments to the Iris Certificate of Incorporation at the special meeting on September 5, 2024. On September 5, 2024, the Company filed with the Secretary of State of the State of Delaware an amendment to its amended and restated certificate of incorporation to change the date by which the Company must consummate a business combination to December 31, 2024.

On October 23, 2024, the parties to the Business Combination Agreement amended the Business Combination Agreement to, among other things, reduce the enterprise value associated with Liminatus to $175 million. On October 31, 2024, the parties to the Subscription Agreement entered into an amendment to such agreement to reduce the PIPE Investor’s equity investment commitment to $15 million.

On December 9, 2024, the Company filed a proxy statement with the SEC containing a proposal to stockholders to amend the Iris Certificate of Incorporation to extend the date by which the Company must consummate a business combination from December 31, 2024 to March 31, 2025 (subject to an additional three month extension at the discretion of the Iris Board). The Company’s stockholders approved the amendments to the Iris Certificate of Incorporation at the special meeting on December 20, 2024. On December 26, 2024, the Company filed with the Secretary of State of the State of Delaware an amendment to its amended and restated certificate of incorporation to change the date by which the Company must consummate a business combination to March 31, 2025 (subject to an additional three month extension at the discretion of the Iris Board).

On December 26, 2024, the parties to the Business Combination Agreement amended the Business Combination Agreement to extend the Outside Date to June 30, 2025. Also on December 26, 2024, the parties to the Subscription Agreement entered into an amendment to such agreement to extend the termination date of the agreement to June 30, 2025.

Effect of the Business Combination on Existing Iris Equity

Subject to the